182 related articles for article (PubMed ID: 22935680)
21. Safety profile of RNAi nanomedicines.
Barros SA; Gollob JA
Adv Drug Deliv Rev; 2012 Dec; 64(15):1730-7. PubMed ID: 22732527
[TBL] [Abstract][Full Text] [Related]
22. Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach.
Solmesky LJ; Shuman M; Goldsmith M; Weil M; Peer D
Nanotechnology; 2011 Dec; 22(49):494016. PubMed ID: 22101838
[TBL] [Abstract][Full Text] [Related]
23. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
[TBL] [Abstract][Full Text] [Related]
24. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response.
Mizrahy S; Raz SR; Hasgaard M; Liu H; Soffer-Tsur N; Cohen K; Dvash R; Landsman-Milo D; Bremer MG; Moghimi SM; Peer D
J Control Release; 2011 Dec; 156(2):231-8. PubMed ID: 21745506
[TBL] [Abstract][Full Text] [Related]
25. Delivery of RNAi therapeutics: work in progress.
Miller AD
Expert Rev Med Devices; 2013 Nov; 10(6):781-811. PubMed ID: 24195461
[TBL] [Abstract][Full Text] [Related]
26. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
27. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
28. Single-step assembly of cationic lipid-polymer hybrid nanoparticles for systemic delivery of siRNA.
Yang XZ; Dou S; Wang YC; Long HY; Xiong MH; Mao CQ; Yao YD; Wang J
ACS Nano; 2012 Jun; 6(6):4955-65. PubMed ID: 22646867
[TBL] [Abstract][Full Text] [Related]
29. Hyaluronic acid modification of RNase A and its intracellular delivery using lipid-like nanoparticles.
Wang X; Li Y; Li Q; Neufeld CI; Pouli D; Sun S; Yang L; Deng P; Wang M; Georgakoudi I; Tang S; Xu Q
J Control Release; 2017 Oct; 263():39-45. PubMed ID: 28153764
[TBL] [Abstract][Full Text] [Related]
30. Investigating impacts of surface charge on intraocular distribution of intravitreal lipid nanoparticles.
Huang X; Chau Y
Exp Eye Res; 2019 Sep; 186():107711. PubMed ID: 31238078
[TBL] [Abstract][Full Text] [Related]
31. A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes.
Ramishetti S; Hazan-Halevy I; Palakuri R; Chatterjee S; Naidu Gonna S; Dammes N; Freilich I; Kolik Shmuel L; Danino D; Peer D
Adv Mater; 2020 Mar; 32(12):e1906128. PubMed ID: 31999380
[TBL] [Abstract][Full Text] [Related]
32. Delivery of small interfering RNA to mammalian cells in culture by using cationic lipid/polymer-based transfection reagents.
Brazas RM; Hagstrom JE
Methods Enzymol; 2005; 392():112-24. PubMed ID: 15644178
[TBL] [Abstract][Full Text] [Related]
33. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
Spagnou S; Miller AD; Keller M
Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141
[TBL] [Abstract][Full Text] [Related]
34. Photoinduced RNA interference.
Matsushita-Ishiodori Y; Ohtsuki T
Acc Chem Res; 2012 Jul; 45(7):1039-47. PubMed ID: 22360585
[TBL] [Abstract][Full Text] [Related]
35. Impact of lipid substitution on assembly and delivery of siRNA by cationic polymers.
Aliabadi HM; Landry B; Bahadur RK; Neamnark A; Suwantong O; Uludağ H
Macromol Biosci; 2011 May; 11(5):662-72. PubMed ID: 21322108
[TBL] [Abstract][Full Text] [Related]
36. Altering the immune response with lipid-based nanoparticles.
Landesman-Milo D; Peer D
J Control Release; 2012 Jul; 161(2):600-8. PubMed ID: 22230342
[TBL] [Abstract][Full Text] [Related]
37. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
[TBL] [Abstract][Full Text] [Related]
38. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
[TBL] [Abstract][Full Text] [Related]
39. RNAi therapeutics: the teenage years.
Perkel JM
Biotechniques; 2012 Jun; 52(6):355-7. PubMed ID: 22668413
[No Abstract] [Full Text] [Related]
40. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
Suzuki Y; Ishihara H
Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
